- Home
- ZNTL vs STRO Comparison
ZNTL vs STRO Comparison
Compare ZNTL & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- STRO
- Stock Information
- Founded
- ZNTL 2014
- STRO 2003
- Country
- ZNTL United States
- STRO United States
- Employees
- ZNTL N/A
- STRO N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZNTL Health Care
- STRO Health Care
- Exchange
- ZNTL Nasdaq
- STRO Nasdaq
- Market Cap
- ZNTL 118.3M
- STRO 96.6M
- IPO Year
- ZNTL 2020
- STRO 2018
- Fundamental
- Price
- ZNTL $1.53
- STRO $1.05
- Analyst Decision
- ZNTL Buy
- STRO Hold
- Analyst Count
- ZNTL 6
- STRO 7
- Target Price
- ZNTL $6.53
- STRO $1.97
- AVG Volume (30 Days)
- ZNTL 751.6K
- STRO 1.6M
- Earning Date
- ZNTL 11-06-2025
- STRO 11-10-2025
- Dividend Yield
- ZNTL N/A
- STRO N/A
- EPS Growth
- ZNTL N/A
- STRO N/A
- EPS
- ZNTL N/A
- STRO N/A
- Revenue
- ZNTL $26,865,000.00
- STRO $104,473,000.00
- Revenue This Year
- ZNTL N/A
- STRO $65.48
- Revenue Next Year
- ZNTL N/A
- STRO N/A
- P/E Ratio
- ZNTL N/A
- STRO N/A
- Revenue Growth
- ZNTL N/A
- STRO N/A
- 52 Week Low
- ZNTL $1.01
- STRO $0.52
- 52 Week High
- ZNTL $4.44
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.74
- STRO 55.33
- Support Level
- ZNTL $1.49
- STRO $1.02
- Resistance Level
- ZNTL $1.82
- STRO $1.18
- Average True Range (ATR)
- ZNTL 0.11
- STRO 0.12
- MACD
- ZNTL 0.00
- STRO 0.02
- Stochastic Oscillator
- ZNTL 11.43
- STRO 51.79
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.